XML 190 R32.htm IDEA: XBRL DOCUMENT
v3.20.4

Company Operations by Product, Customer and Geographic Area | 12 Months Ended
--- | ---
Dec. 31, 2020
Segment Reporting [Abstract] |
Company Operations by Product, Customer and Geographic Area | Company Operations by Product, Customer and Geographic Area We have determined that we operate in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The following table presents a summary of total revenues by these products for the twelve months ended December 31, 2020, 2019, and 2018:
Revenue by Product: |  | 2020 |  | 2019 |  | 2018
Bloxiverz |  | $ | 2,201 |  |  | $ | 7,479 |  |  | $ | 20,850 |
Vazculep |  | 10,429 |  |  | 33,152 |  |  | 42,916 |
Akovaz |  | 9,545 |  |  | 18,642 |  |  | 33,759 |
Other |  | 159 |  |  | (58) |  |  | 3,898 |
Product sales |  | 22,334 |  |  | 59,215 |  |  | 101,423 |
License revenue |  | — |  |  | — |  |  | 1,846 |
Total revenues |  | $ | 22,334 |  |  | $ | 59,215 |  |  | $ | 103,269 |
Concentration of credit risk with respect to accounts receivable is limited due to the high credit quality comprising a significant portion of the Company’s customers. Management periodically monitors the creditworthiness of our customers and believes that we have adequately provided for any exposure to potential credit loss. The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2020, 2019, and 2018:
Revenue by Significant Customer: |  | 2020 |  | 2019 |  | 2018
McKesson Corporation |  | $ | 5,758 |  |  | $ | 14,900 |  |  | $ | 26,794 |
Cardinal Health |  | 5,155 |  |  | 15,088 |  |  | 25,413 |
AmerisourceBergen |  | 3,155 |  |  | 12,059 |  |  | 18,620 |
QuVa Pharma |  | 3,117 |  |  | 3,252 |  |  | 2,788 |
Others |  | 5,149 |  |  | 13,916 |  |  | 27,808 |
Product sales |  | 22,334 |  |  | 59,215 |  |  | 101,423 |
License revenue |  | — |  |  | — |  |  | 1,846 |
Total revenues |  | $ | 22,334 |  |  | $ | 59,215 |  |  | $ | 103,269 |
The following table summarizes revenues by geographic region for the twelve months ended December 31, 2020, 2019, and 2018:
Revenue by Geographic Region: |  | 2020 |  | 2019 |  | 2018
U.S. |  | $ | 22,334 |  |  | $ | 59,215 |  |  | $ | 101,423 |
Ireland |  | — |  |  | — |  |  | 1,846 |
Total revenues |  | $ | 22,334 |  |  | $ | 59,215 |  |  | $ | 103,269 |
Currently, we are working with contract manufacturing organizations for the manufacture of FT218. Additionally, we purchase raw materials used in FT218 from a limited number of suppliers, including a single supplier for certain key ingredients. Non-monetary long-lived assets primarily consist of property and equipment, goodwill, intangible assets and operating right-of use-assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2020, 2019, and 2018:
Long-lived Assets by Geographic Region: |  | 2020 |  | 2019 |  | 2018
U.S. |  | $ | 20,424 |  |  | $ | 22,254 |  |  | $ | 27,761 |
France |  | 11 |  |  | 196 |  |  | 1,365 |
Ireland |  | 6,047 |  |  | 7,244 |  |  | 6,028 |
Total |  | $ | 26,482 |  |  | $ | 29,694 |  |  | $ | 35,154 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration